Lercanidipine Actavis (Lercanidipine Hydrochloride)

Lercanidipine selectively blocks L‑type calcium channels on arterial smooth‑muscle cells. This inhibition prevents calcium entry, leading to relaxation of the vascular smooth muscle, vasodilation, and a subsequent decrease in peripheral resistance and arterial pressure.

The appropriate dose of lercanidipine is determined by the prescribing healthcare professional based on the individual’s clinical condition, response to therapy, and any concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of lercanidipine in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lercanidipine belongs to the dihydropyridine calcium‑channel blocker class, offering potent vasodilation with a relatively low incidence of reflex tachycardia compared with non‑dihydropyridine agents. Unlike ACE inhibitors or ARBs, it does not affect the renin‑angiotensin system, making it a useful option for patients who cannot tolerate those classes.

Lercanidipine Actavis tablets should be stored at ambient temperature, below 25 °C, in the original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain its stability and potency.

The medication is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with a glass of water and avoid crushing or chewing it, unless otherwise directed by a healthcare professional.

Serious adverse events, though rare, include severe hypotension, myocardial infarction, hepatic dysfunction, allergic reactions such as rash or urticaria, and angioedema. Patients should seek immediate medical attention if they experience symptoms like fainting, chest pain, severe dizziness, or swelling of the face or throat.

Lercanidipine is contraindicated in patients with known hypersensitivity to the drug or any component of the formulation. Caution is advised for individuals with severe hepatic impairment, uncontrolled heart failure, or those taking strong CYP3A4 inhibitors without appropriate monitoring.